Volume 16, Number 6—June 2010
Enterovirus Genotype EV-104 in Humans, Italy, 2008–2009
|Patient no.||Sample no.||Age, y/sex||Hospital department, date of admission||Respiratory secretion Ct value
||Clinical symptoms||Underlying disease||Virus identified/ coinfecting virus (Ct)|
|Pav-1||NPA/9210||60/M||Hematology outpatient, Apr||29.67||Undetected||Fever, cough, rhinorrhea||HSCT (AML)||EV-104|
|Pav-2||NPA/9570||62/M||Infectious Diseases outpatient, Apr||23.06||23.05||Chronic rhinopharyngitis||None||EV-104|
|Pav-3||NPA/11228||7/F||Pediatric Oncohematology, May||33.64||Undetected||Fever, rhinorrhea, conjunctivitis||AML (chemotherapy)||EV-104|
|Pav-4||NPA/11230||37/F||Infectious Diseases outpatient, May||32.60||Undetected||Chronic rhinopharyngitis||None||EV-104|
|Pav-5||NPA/13174||2/M||Pediatric Oncohematology, Jun||23.78||31.61||Cough, rhinorrhea, diarrhea, wheezing||HSCT (AML)||EV-104/RSV (18.53)|
*HEV, human enterovirus; Ct, cycle threshold; HRV, human rhinovirus; NPA, nasopharyngeal aspirate; HSCT, hematopoietic stem cell transplant; AML, acute myelocytic leukemia; RSV, respiratory syncytial virus.
Page created: February 10, 2011
Page updated: February 10, 2011
Page reviewed: February 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.